



## Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

**MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3<sup>rd</sup> May, 2019.** Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9<sup>th</sup> May 2019.

Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5<sup>th</sup> May featuring data from the company’s Phase 1 clinical trial and a Poster Presentation featuring pre-clinical data on Thursday 9<sup>th</sup> May.

The American Academy of Neurology Annual Meeting is one of the largest gatherings of clinicians and researchers focusing on neurology in the world. It has been running for more than 70 years.

The Platform Presentation is titled: *A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of  $\alpha$ -Synuclein Aggregation* and will present first data from the current clinical study program. Details of this presentation, which is to be delivered by David Stamler, MD, Chief Medical Officer & Senior VP Clinical Development, will be disclosed to investors concurrently with the presentation.

The Phase 1 Clinical Trial for PBT434 commenced in 2018 in Australia, recruiting healthy adult and older adult ( $\geq 65$ ) volunteers with the primary goals of assessing the safety and tolerability of PBT434 after single and multiple oral dose administration. Secondary goals include evaluating pharmacokinetic measures that will allow Alterity understand how PBT434 is absorbed and metabolised by the body.

The Poster Presentation appearing on Thursday 9<sup>th</sup> May is titled: *PBT434 Prevents  $\alpha$ -Synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy*<sup>1</sup>.

This study evaluated the efficacy of PBT434 in a mouse model of multiple system atrophy (MSA), which is a rare and rapidly progressive neurological disorder that affects adults. MSA is characterized by motor symptoms similar to those found in Parkinson’s disease, loss of ability to coordinate voluntary movements, and impaired ability to regulate involuntary body functions such as blood pressure, bowel and bladder control and sexual function. Symptoms typically commence between the ages of 50 and 60 years of age and it has no known cause. The Poster will be lodged to coincide with the session later in the week.

PBT434 is the first of a new generation of small molecules designed to block the accumulation and aggregation of  $\alpha$ -synuclein.  $\alpha$ -synuclein is of great interest because aggregated forms of the protein are considered a pathological hallmark of Parkinsonian conditions and are a recognised therapeutic target by neuroscientists and clinicians.

For personal use only

## Session details:

### Oral Presentation Session:

- First in Human Study of PBT434, a Novel Small Molecule Inhibitor of  $\alpha$ -Synuclein Aggregation
- Session S4: Clinical Trials in Movement Disorders, Sunday May 5, 1:00 pm US ET
- Presentation number 001

### Poster Presentation Sessions:

- Abstract number 837; PBT434 Prevents  $\alpha$ -Synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy<sup>ii</sup>
- Poster Session P5, Thursday May 9, 11:30am to 6:30pm US ET
- Poster presentation number 8-006

Geoffrey Kempler, CEO and Chairman said: *"The AAN is the most prestigious gathering of clinicians and researching working in neurology and we are very pleased to have such strong participation which speaks to the novelty and promise of our PBT434 drug candidate for the treatment of neurological diseases."*

### End Note

The Company changed its name on 8 April 2019 from Prana Biotechnology Limited to Alterity Therapeutics Limited, (ASX: ATH, NASDAQ:ATHE).

Investor enquiries [IR@alteritytherapeutics.com](mailto:IR@alteritytherapeutics.com)

### Contact:

#### Investor Relations

Rebecca Wilson

E: [rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Tp: +61 3 9866 4722

### About Alterity Therapeutics Limited

Alterity's lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of  $\alpha$ -synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).

For further information please visit the Company's web site at [www.alteritytherapeutics.com](http://www.alteritytherapeutics.com).

## Forward Looking Statements

*This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.*

*Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT434, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT434.*

*Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly updated any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.*

---

<sup>i</sup> *PBT434 Prevents  $\alpha$ -synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy [David Finkelstein<sup>1</sup>, Nadia Stefanova<sup>2</sup>, Paul Adlard<sup>1</sup>, Margaret Bradbury<sup>3</sup>, David Stamler<sup>3</sup> <sup>1</sup>Florey Institute of Neuroscience, <sup>2</sup>Medical University of Innsbruck, <sup>3</sup>Prana Biotechnology]*

<sup>ii</sup> *PBT434 Prevents  $\alpha$ -synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy [David Finkelstein<sup>1</sup>, Nadia Stefanova<sup>2</sup>, Paul Adlard<sup>1</sup>, Margaret Bradbury<sup>3</sup>, David Stamler<sup>3</sup> <sup>1</sup>Florey Institute of Neuroscience, <sup>2</sup>Medical University of Innsbruck, <sup>3</sup>Prana Biotechnology]*